Trials / Terminated
TerminatedNCT02760602
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Solanezumab | Administered IV |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
- First posted
- 2016-05-03
- Last updated
- 2019-10-10
- Results posted
- 2018-07-24
Locations
193 sites across 13 countries: United States, Canada, Finland, France, Germany, Italy, Japan, Poland, Puerto Rico, Spain, Sweden, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02760602. Inclusion in this directory is not an endorsement.